As the world leader of cell line manufacturing, Selexis is now offering a portfolio of cell lines expressing biosimilar recombinant protein drugs with added characterization services
GENEVA, March 31 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services for the rapid development of high-performance stable production cell lines announced today an expanded offering focusing on the biosimilar market segment. Under the new program, Selexis will offer clients the contract development of high producing mammalian cell lines expressing biosimilars, including expanded characterization capabilities. Selexis scientists have already demonstrated, using the Selexis SURE Cell Line Development(SM) Platform, the production of biosimilars proteins at levels as much as 50 fold greater than the currently marketed drugs. The Selexis' SURE Cell Line Development(SM) platform combines Selexis' Intellectual Property rights (e.g. novel genetic elements DNA sequences and transfection procedures) with its cell culture know-how for the rapid development of biosimilars products.
Dr. Igor Fisch, President and CEO of Selexis, commented:
"We feel it is a very important step towards the creation of a global company offering fully integrated services to our client worldwide by including biosimilar expressing cell lines Importantly, in support of this new offer, we are also expanding our support of product characterization capabilities which will further enhance the value of this package".
By combining proprietary technologies with know-how on a fully integrated platform, Selexis can provide top performance cell lines in a industry-known and accepted package.
Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.
Copyright©2009 PR Newswire.
All rights reserved